Text Size
Trial record 5 of 211 for:    Open Studies | "Hepatitis B"
Previous Study | Return to List | Next Study

Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by China Medical University Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01311947
First received: March 8, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

In order to clarify the association between HBV mutations appearing before and during interferon therapy and the therapeutic effects, serial serum samples from 100 HBeAg-positive CHB patients undergoing peginterferon alfa-2a therapy will be collected and analyzed for the mutations of preS/S gene and BCP-preC/C region, particularly for the deletion mutations. Furthermore, Real-Time PCR will be performed to measure the ratios of wild-type HBV and deletion mutant HBV before and at the end of peginterferon alfa-2a therapy. Finally, statistical analysis will be done to elucidate whether the mutations of preS/S gene and BCP-preC/C region have any relation with the therapeutic effect of peginterferon alfa-2a.


Condition Intervention
Hepatitis B, Chronic
 Drug: Peginterferon alfa-2a

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Relation of Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by China Medical University Hospital:

Primary Outcome Measures:
  • Therapeutic response to Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B [ Time Frame: 24 weeks after the end of 24 weeks of Peginterferon alfa-2a treatment ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Serum specimens


Estimated Enrollment: 100
Study Start Date: March 2011
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Peginterferon alfa-2a Drug: Peginterferon alfa-2a
Peginterferon alfa-2a at 180 ug weekly for 24 weeks
Other Name: Pegasys

Detailed Description:

Hepatitis B virus (HBV) infection is a serious worldwide health issue. Approximately 400 million people worldwide are chronic hepatitis B (CHB) patients. Currently, two therapeutic methods can be used to treat CHB. One is the nucleos(t)ide analogues, the other is the interferon alfa. Interferon alfa acts mainly by enhancing the immune system and directly inhibits the virus to a limited extent. It is known that mutations at preS, S, basal core promoter, precore and core gene are associated with an increased risk of HCC. However, it remains to be clarified as to the relation between HBV mutations and the therapeutic responses to interferon treatment. In order to clarify the association between HBV mutations appearing before and during interferon therapy and the therapeutic effects, serial serum samples from 100 HBeAg-positive CHB patients undergoing peginterferon alfa-2a therapy will be collected and analyzed for the mutations of preS/S gene and BCP-preC/C region, particularly for the deletion mutations. Furthermore, Real-Time PCR will be performed to measure the ratios of wild-type HBV and deletion mutant HBV before and at the end of peginterferon alfa-2a therapy. Finally, statistical analysis will be done to elucidate whether the mutations of preS/S gene and BCP-preC/C region have any relation with the therapeutic effect of peginterferon alfa-2a.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

HBeAg-positive chronic hepatitis B

Criteria

Inclusion Criteria:

HBeAg-positive chronic hepatitis B patients on Peginterferon therapy

Exclusion Criteria:

HBeAg-negative chronic hepatitis B patients HBeAg-positive chronic hepatitis B patients on other kinds of therapy

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01311947

Contacts
Contact: Cheng-Yuan Peng, MD, PhD 886-4-22052121 ext 2264 cypeng@mail.cmuh.org.tw

Locations
Taiwan
China Medical University Hospital Not yet recruiting
Taichung, Taiwan, 404
Contact: Cheng-Yuan Peng, MD, PhD     886-4-22052121 ext 2264     cypeng@mail.cmuh.org.tw    
Principal Investigator: Cheng-Yuan Peng, MD, PhD            
Sponsors and Collaborators
China Medical University Hospital
Investigators
Principal Investigator: Cheng-Yuan Peng, MD, PhD China Medical University Hospital
  More Information

Publications:

Responsible Party: Cheng-Yuan Peng, China Medical University Hospital
ClinicalTrials.gov Identifier: NCT01311947     History of Changes
Other Study ID Numbers: DMR99-IRB-313
Study First Received: March 8, 2011
Last Updated: March 8, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by China Medical University Hospital:
Chronic hepatitis B
Peginterferon alfa-2a

Additional relevant MeSH terms:
Hepatitis B
Hepatitis B, Chronic
Hepatitis
Hepatitis A
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
 RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Peginterferon alfa-2a
Interferon-alpha
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 18, 2013